

Haematologica  
HAEMATOL/2019/236877  
Version 3

Characterization of breakthrough hemolysis events observed in the  
phase 3 randomized studies of ravulizumab versus eculizumab in  
adults with paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky, Régis Peffault de Latour, Scott T. Rottinghaus,  
Alexander Röth, Antonio M. Risitano, Ilene C. Weitz, Peter Hillmen,  
Jaroslaw P. Maciejewski, Jeff Szer, Jong Wook Lee, Austin G.  
Kulasekararaj, Lori Volles, Andrew I. Damokosh, Stephan Ortiz, Lori  
Shafner, Peng Liu, Anita Hill, and Hubert Schrezenmeier

Disclosures: Robert A. Brodsky is a member of the scientific advisory board for and receives grant funding from Alexion Pharmaceuticals, Inc. Régis Peffault de Latour has received honoraria, consulting fees, and research support from Alexion Pharmaceuticals, Inc., Pfizer, and Novartis, and has received research support from Amgen. Scott T. Rottinghaus is an employee and stockholder of Alexion Pharmaceuticals, Inc. Alexander Röth has received honoraria and consulting fees from Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals, Novartis, and Roche. Antonio M. Risitano has received research support, honoraria, and consulting fees from Alexion Pharmaceuticals, Inc., Novartis, Alnylam, and Ra Pharma, lecture fees from Alexion Pharmaceuticals, Inc., Novartis, Pfizer, and Jazz, and served as an advisory board member for Alexion Pharmaceuticals, Inc., Novartis, Pfizer, and Jazz, as well as consultant for Amyndas. Ilene C. Weitz has received honoraria and consulting fees from Alexion Pharmaceuticals, Inc. Peter Hillmen has received honoraria from and has been a consultant for Alexion Pharmaceuticals, Inc., and has received research support (to the University of Leeds) from Apellis Pharmaceuticals. Jaroslaw P. Maciejewski has received consulting fees from Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals, and Ra Pharma; has also received speaker fees from and is a member of the Executive Committee of the International PNH Registry for Alexion Pharmaceuticals, Inc. Jeff Szer has received research support (to Royal Melbourne Hospital), honoraria, consulting fees, and travel support from Alexion Pharmaceuticals, Inc. Jong Wook Lee has received honoraria, consulting fees, and research support (to Seoul St. Mary's Hospital) from Alexion Pharmaceuticals, Inc. Austin G. Kulasekararaj has received honoraria, travel support, and consulting fees from Alexion Pharmaceuticals, Inc. Lori Volles is an employee and stockholder of Alexion Pharmaceuticals, Inc. Andrew I. Damokosh was an employee and stockholder of Alexion Pharmaceuticals, Inc. at the time of the study analysis and during the development of this manuscript. Stephan Ortiz is an employee and stockholder of Alexion Pharmaceuticals, Inc. Lori Shafner was an employee and stockholder of Alexion Pharmaceuticals, Inc. at the time of this analysis and during development of the manuscript. Peng Liu is an employee and stockholder of Alexion Pharmaceuticals, Inc. Anita Hill has received honoraria and consulting fees from Alexion Pharmaceuticals, Inc. Hubert Schrezenmeier has received honoraria and research support (both to University of Ulm) from Alexion Pharmaceuticals, Inc.

Contributions: Study design: AH, AID, AR, PH, HS, RPL, JWL, AK, LS, LV, STR Study investigator: AH, AR, RAB, RPL, AMR, ICW, PH, JPM, JS, JWL, AK, HS Enrolled patients: AH, AR, RAB, RPL, AMR, ICW, PH, JPM, JS, JWL, AK, HS Collection and assembly of data: All authors Data analysis: AR, AID, HS, PL, SO, STR, RAB Data interpretation: All authors Manuscript review and revisions: All authors Final approval of manuscript: All authors